Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockadeKei Ishibashi(Okayama University Hospital), Yoshiyuki Kojima(Fukushima Medical University)OncotargetJuly 21, 201710.18632/oncotarget.19420Cited by 55SaveCiteExport RISWatch citationsRelated PapersImpact of Sulfatase‐2 on cancer progression and prognosis in patients with renal cell carcinoma|Cancer Science|2016|14l-Theanine Protects Bladder Function by Suppressing Chronic Sympathetic Hyperactivity in Spontaneously Hypertensive Rat|Metabolites|2021|11Involvement of Mast-Cell-Tryptase- and Protease-Activated Receptor 2—Mediated Signaling and Urothelial Barrier Dysfunction with Reduced Uroplakin II Expression in Bladder Hyperactivity Induced by Chronic Bladder Ischemia in the Rat|International Journal of Molecular Sciences|2023|7